IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors

Standard

IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors. / Beyranvand Nejad, Elham; Labrie, Camilla; van Elsas, Marit J; Kleinovink, Jan Willem; Mittrücker, Hans-Willi; Franken, Kees L M C; Heink, Sylvia; Korn, Thomas; Arens, Ramon; van Hall, Thorbald; van der Burg, Sjoerd H.

in: J IMMUNOTHER CANCER, Jahrgang 9, Nr. 4, e002460, 04.2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Beyranvand Nejad, E, Labrie, C, van Elsas, MJ, Kleinovink, JW, Mittrücker, H-W, Franken, KLMC, Heink, S, Korn, T, Arens, R, van Hall, T & van der Burg, SH 2021, 'IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors', J IMMUNOTHER CANCER, Jg. 9, Nr. 4, e002460. https://doi.org/10.1136/jitc-2021-002460

APA

Beyranvand Nejad, E., Labrie, C., van Elsas, M. J., Kleinovink, J. W., Mittrücker, H-W., Franken, K. L. M. C., Heink, S., Korn, T., Arens, R., van Hall, T., & van der Burg, S. H. (2021). IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors. J IMMUNOTHER CANCER, 9(4), [e002460]. https://doi.org/10.1136/jitc-2021-002460

Vancouver

Bibtex

@article{ac64403dff91459b8d84cc9949e0870c,
title = "IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors",
abstract = "BACKGROUND: High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective.METHODS: IL-6 and IL-6R blockade was applied in an IL-6-mediated immunotherapy-resistant TC-1 tumor model (TC-1.IL-6) and immunotherapy-sensitive TC-1.CONTROL: Effects on therapeutic vaccination-induced tumor regression, recurrence and survival as well on T cells and myeloid cells in the tumor microenvironment were studied. The effects of IL-6 signaling in macrophages under therapy conditions were studied in Il6rafl/fl×LysMcre+ mice.RESULTS: Our therapeutic vaccination protocol elicits a strong tumor-specific CD8+ T-cell response, leading to enhanced intratumoral T-cell infiltration and recruitment of tumoricidal macrophages. Blockade of IL-6 signaling exacerbated tumor outgrowth, reflected by fewer complete regressions and more recurrences after therapeutic vaccination, especially in TC-1.IL-6 tumor-bearing mice. Early IL-6 signaling blockade partly inhibited the development of the vaccine-induced CD8+ T-cell response. However, the main mechanism was the malfunction of macrophages during therapy-induced tumor regression. Therapy efficacy was impaired in Il6rafl/fl×LysMcre+ but not cre-negative control mice, while no differences in the vaccine-induced CD8+ T-cell response were found between these mice. IL-6 signaling blockade resulted in decreased expression of suppressor of cytokine signaling 3, essential for effective M1-type function in macrophages, and increased expression of the phagocytic checkpoint molecule signal-regulatory protein alpha by macrophages.CONCLUSION: IL-6 signaling is critical for macrophage function under circumstances of immunotherapy-induced tumor tissue destruction, in line with the acute inflammatory functions of IL-6 signaling described in infections.",
author = "{Beyranvand Nejad}, Elham and Camilla Labrie and {van Elsas}, {Marit J} and Kleinovink, {Jan Willem} and Hans-Willi Mittr{\"u}cker and Franken, {Kees L M C} and Sylvia Heink and Thomas Korn and Ramon Arens and {van Hall}, Thorbald and {van der Burg}, {Sjoerd H}",
note = "{\textcopyright} Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2021",
month = apr,
doi = "10.1136/jitc-2021-002460",
language = "English",
volume = "9",
journal = "J IMMUNOTHER CANCER",
issn = "2051-1426",
publisher = "BioMed Central Ltd.",
number = "4",

}

RIS

TY - JOUR

T1 - IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors

AU - Beyranvand Nejad, Elham

AU - Labrie, Camilla

AU - van Elsas, Marit J

AU - Kleinovink, Jan Willem

AU - Mittrücker, Hans-Willi

AU - Franken, Kees L M C

AU - Heink, Sylvia

AU - Korn, Thomas

AU - Arens, Ramon

AU - van Hall, Thorbald

AU - van der Burg, Sjoerd H

N1 - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2021/4

Y1 - 2021/4

N2 - BACKGROUND: High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective.METHODS: IL-6 and IL-6R blockade was applied in an IL-6-mediated immunotherapy-resistant TC-1 tumor model (TC-1.IL-6) and immunotherapy-sensitive TC-1.CONTROL: Effects on therapeutic vaccination-induced tumor regression, recurrence and survival as well on T cells and myeloid cells in the tumor microenvironment were studied. The effects of IL-6 signaling in macrophages under therapy conditions were studied in Il6rafl/fl×LysMcre+ mice.RESULTS: Our therapeutic vaccination protocol elicits a strong tumor-specific CD8+ T-cell response, leading to enhanced intratumoral T-cell infiltration and recruitment of tumoricidal macrophages. Blockade of IL-6 signaling exacerbated tumor outgrowth, reflected by fewer complete regressions and more recurrences after therapeutic vaccination, especially in TC-1.IL-6 tumor-bearing mice. Early IL-6 signaling blockade partly inhibited the development of the vaccine-induced CD8+ T-cell response. However, the main mechanism was the malfunction of macrophages during therapy-induced tumor regression. Therapy efficacy was impaired in Il6rafl/fl×LysMcre+ but not cre-negative control mice, while no differences in the vaccine-induced CD8+ T-cell response were found between these mice. IL-6 signaling blockade resulted in decreased expression of suppressor of cytokine signaling 3, essential for effective M1-type function in macrophages, and increased expression of the phagocytic checkpoint molecule signal-regulatory protein alpha by macrophages.CONCLUSION: IL-6 signaling is critical for macrophage function under circumstances of immunotherapy-induced tumor tissue destruction, in line with the acute inflammatory functions of IL-6 signaling described in infections.

AB - BACKGROUND: High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective.METHODS: IL-6 and IL-6R blockade was applied in an IL-6-mediated immunotherapy-resistant TC-1 tumor model (TC-1.IL-6) and immunotherapy-sensitive TC-1.CONTROL: Effects on therapeutic vaccination-induced tumor regression, recurrence and survival as well on T cells and myeloid cells in the tumor microenvironment were studied. The effects of IL-6 signaling in macrophages under therapy conditions were studied in Il6rafl/fl×LysMcre+ mice.RESULTS: Our therapeutic vaccination protocol elicits a strong tumor-specific CD8+ T-cell response, leading to enhanced intratumoral T-cell infiltration and recruitment of tumoricidal macrophages. Blockade of IL-6 signaling exacerbated tumor outgrowth, reflected by fewer complete regressions and more recurrences after therapeutic vaccination, especially in TC-1.IL-6 tumor-bearing mice. Early IL-6 signaling blockade partly inhibited the development of the vaccine-induced CD8+ T-cell response. However, the main mechanism was the malfunction of macrophages during therapy-induced tumor regression. Therapy efficacy was impaired in Il6rafl/fl×LysMcre+ but not cre-negative control mice, while no differences in the vaccine-induced CD8+ T-cell response were found between these mice. IL-6 signaling blockade resulted in decreased expression of suppressor of cytokine signaling 3, essential for effective M1-type function in macrophages, and increased expression of the phagocytic checkpoint molecule signal-regulatory protein alpha by macrophages.CONCLUSION: IL-6 signaling is critical for macrophage function under circumstances of immunotherapy-induced tumor tissue destruction, in line with the acute inflammatory functions of IL-6 signaling described in infections.

U2 - 10.1136/jitc-2021-002460

DO - 10.1136/jitc-2021-002460

M3 - SCORING: Journal article

C2 - 33879600

VL - 9

JO - J IMMUNOTHER CANCER

JF - J IMMUNOTHER CANCER

SN - 2051-1426

IS - 4

M1 - e002460

ER -